Dr. Stephen J. Laquis, MD

Dr. Laquis practices at St. Mark's Surgical Center in Fort Myers, Florida.

Dr. Laquis' NPI, 1588608624, was assigned on June 16, 2006. Dr. Laquis graduated from New York Medical College in 1996. Dr. Laquis holds Florida license ME82974.

Dr. Laquis' primary practice is St. Mark's Surgical Center, at 6820 International Center Blvd, Fort Myers, FL 33912. The practice phone is (239) 210-0301.

Dr. Laquis' primary practice is St. Mark's Surgical Center in Fort Myers, Florida. Dr. Laquis is also affiliated with Gulf Coast Medical Center. Dmand AI also links Dr. Laquis to 1 more group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Laquis practices, 3 sites in all. Vendor and product names are available with a free account.

Ophthalmology is Dr. Laquis' primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Laquis is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Laquis' licenses on file in 3 states: Florida, Kentucky and Tennessee.

Dmand AI lists conjunctivitis, dry eye, eye infection or inflammation, eyelid inflammation and glaucoma among the conditions Dr. Laquis treats.

CMS data shows 4,282 Medicare services from Dr. Laquis across 30 procedure codes in 2024, for 1,333 Medicare patients. Medicare paid $587,586 for them.

CMS counts 1,333 Medicare patients who saw Dr. Laquis in 2024. The largest group is 75 to 84, with 598 patients. 75% of them have high cholesterol, and 71% have high blood pressure. 1% are also on Medicaid. Their average risk score is 1.16, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Laquis' median patient age at 72, with 61% women.

In 2024, Dr. Laquis wrote 2,299 Medicare Part D claims for 1,460 patients. 91% of them were for generic drugs. CMS names the drug for 2,202 of them, across 10 drugs with 11 or more claims each, at $44,523 in total drug cost. In 2023, CMS named 1,888 claims across 10 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Laquis for performance year 2024, reported individually. Dr. Laquis accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 104 procedures of melanoma (skin cancer) excision by Dr. Laquis, more than 93% of the clinicians it reports for that procedure.

Skin biopsy: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 8 papers to Dr. Laquis in 2012. The most frequent topics are Magnetic Resonance Imaging, Melanoma and Tomography, X-Ray Computed. Dr. Laquis has published most often in Am J Ophthalmol. Dr. Laquis' most frequent co-authors are Malena M. Amato, MD, Wilson B. Baber, MD and Vikram David Durairaj, MD.

CMS Open Payments shows 105 general payments to Dr. Laquis from 8 drug and device companies from 2016 to 2025. Honoraria make up the largest share, 66% of the total. Horizon Pharma plc paid the most, $7,484.

Dmand AI lists 4 awards for Dr. Laquis, most recently Gulfshore Life Magazine: Top Doctors in 2014.

Dr. Laquis graduated from New York Medical College in 1996. Dr. Laquis is a member of AAO and ACS.

Dr. Laquis is in network with 17 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 12. Check the plan with the practice before a visit.